RSS-Feed abonnieren
DOI: 10.1055/a-0598-4748
Prevalence of Congenital CMV Infection and Antiviral Therapy in Very-Low-Birth-Weight Infants: Observations of the German Neonatal Network
Prävalenz der kongenitalen CMV Infektion und antivirale Therapie in Very-Low-Birth-Weight Infants: Beobachtungen aus dem German Neonatal NetworkPublikationsverlauf
Publikationsdatum:
18. April 2018 (online)
![](https://www.thieme-connect.de/media/klinpaed/201805/lookinside/thumbnails/1045_10-1055-a-0598-4748-1.jpg)
Abstract
Background To determine the prevalence of congenital CMV infection (cCMV) in very-low-birth-weight infants (VLBWI) and to evaluate epidemiological characteristics of VLBWI with antiviral therapy (AT).
Methods CMV-specific PCR in umbilical cord tissue was performed (n=3330). Univariate analyses and logistic regression models were used to identify associations with outcome.
Results 22/3330 VLBWI received AT (0.66%). 4 of these (0.12%) were PCR positive, with 2 VLBWI showing pathological screening for hearing loss. VLBWI with AT and negative PCR had significantly reduced mean birth weight (BW) and higher rates of small-for-gestational-age (SGA). Clinical sepsis, bronchopulmonary dysplasia (BPD), use of reserve antibiotics (RA) and treatment for retinopathy of prematurity were significantly increased. We further observed a higher need of transfusion of red blood cells (RBC), fresh frozen plasma and platelets. Logistic regression (controlled for gender, gestational age, SGA and BW) showed associations for AT and BPD (OR 3.4 [1.2–10.1], p=0.024), RA (OR 20.4 [4.2–98.9], p≤0.001), transfusions of RBC (OR 11.9 [1.3–105.7], p=0.026) and platelets (OR 8.7 [2.9–26.4], p≤0.001).
Discussion All VLBWI with positive PCR received AT. We hypothesize from our data by assuming a postnatal aquired CMV infection in VLBWI with AT and negative PCR that VLBWI born SGA have a different risk profile.
Conclusion Further prospective studies concerning postnatal transmission should take VLBWI born SGA into account and should study the impact of infection on short- and long-term complications in this supposed vulnerable group.
Zusammenfassung
Hintergrund Bestimmung der Prävalenz kongenitaler CMV-Infektion und Evaluierung epidemiologischer Charakteristika bei very-low-birth-weight infants (VLBWI) mit antiviraler Therapie (AT).
Methoden CMV-spezifische DNA wurde per PCR in Nabelschnurgewebe (n=3330) bestimmt. Univariate und logistische Regressionsanalysen wurden zur Identifizierung von Assoziationen und Outcome herangezogen.
Ergebnisse 22/3330 VLBWI (0,66%) erhielten AT. Ein positiver CMV Nachweis ergab sich bei 4 dieser Kinder (0,12%). 2 davon zeigten ein pathologisches Hörscreening. VLBWI mit AT und negativer PCR zeigten ein signifikant reduziertes mittleres Geburtsgewicht (GG) und höhere Raten an small-for-gestational-age (SGA). Klinische Sepsis, Bronchopulmonale Dysplasie (BPD), Gebrauch von Reserveantibiotika (RA) und Behandlung einer Retinopathia praematorum waren signifikant erhöht. Weiter beobachteten wir erhöhte Transfusionsraten für Erythrozytenkonzentrate (EK), fresh frozen plasma und Thrombozyten (THR). In der logistischen Regression (kontrolliert für Geschlecht, Gestationsalter, SGA und GG) zeigten sich Assoziationen für AT und BPD (OR 3,4 [1,2–10,1], p=0,024), RA (OR 20,4 [4,2–98,9], p≤0,001), Transfusionen von EK (OR 11,9 [1,3–105,7], p=0,026) und THR (OR 8,7 [2,9–26,4], p≤0,001).
Diskussion Alle VLBWI mit positiver PCR erhielten AT. Bei vermutlich postnatal CMV infizierten VLBWI (AT und negative PCR) vermuten wir aus der Analyse unserer Daten ein besonderes Risikoprofil bei SGA Kindern.
Schlussfolgerung Weitere prospektive Studien bezüglich postnataler Transmission sollten VLBWI mit SGA in den Fokus nehmen und den Einfluss auf Kurz- und Langzeiteffekte besonders in dieser Kohorte untersuchen.
-
References
- 1 Assinger A. Platelets and infection – an emerging role of platelets in viral infection. Front Immunol 2014; 5: 649
- 2 Cannon MJ, Griffiths PD, Aston V. et al. Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit?. Rev Med Virol 2014; 24: 291-307
- 3 Eldar-Yedidia Y, Bar-Meir M, Hillel M. et al. Low Interferon Relative-Response to Cytomegalovirus Is Associated with Low Likelihood of Intrauterine Transmission of the Virus. PLoS One 2016; 11: e0147883
- 4 Furutate S, Iwasaki S, Nishio S. et al. Clinical profile of hearing loss in children with congenital cytomegalovirus (CMV) infection: CMV DNA diagnosis using preserved umbilical cord. Acta Otolaryngol 2011; 131: 976-982
- 5 Gunkel J, de Vries LS, Jongmans M. et al Outcome of Preterm Infants With Postnatal Cytomegalovirus Infection. Pediatrics 2018; 141: e20170635
- 6 Hamprecht K, Goelz R. Postnatal Cytomegalovirus Infection Through Human Milk in Preterm Infants. Clin Perinatol 2017; 44: 121-130
- 7 Hosseeini S, Ansari S, Kalantar E. et al. A fetal hemolytic anemia in a child with cytomegalovirus infection. Iran J Pediatr Hematol Oncol 2014; 4: 78-83
- 8 Hraiech S, Bordes J, Mège JL. et al. Cytomegalovirus reactivation enhances the virulence of Staphylococcus aureus pneumonia in a mouse model. Clin Microbiol Infect 2017; 23: 38-45
- 9 Hughes BL, Gyamfi-Bannerman C. Diagnosis and antenatal management of congenital cytomegalovirus infection. Am J Obstet Gynecol 2016; 214: B5-B11
- 10 Ikeda S, Tsuru A, Moriuchi M. et al. Retrospective diagnosis of congenital cytomegalovirus infection using umbilical cord. Pediatr Neurol 2006; 34: 415-416
- 11 Jacobsen T, Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Heal Pharm 2010; 67: 1417-1425
- 12 James SH, Kimberlin DW. Advances in the prevention and treatment of congenital cytomegalovirus infection. Curr Opin Pediatr 2016; 28: 81-85
- 13 Kaneko M, Ohhashi M, Minematsu T. et al. Maternal immunoglobulin G avidity as a diagnostic tool to identify pregnant women at risk of congenital cytomegalovirus infection. J Infect Chemother 2017; 23: 173-176
- 14 Kelly MS, Benjamin DK, Puopolo KM. et al. Postnatal Cytomegalovirus Infection and the Risk for Bronchopulmonary Dysplasia. JAMA Pediatr 2015; 169: e153785
- 15 Kimberlin DW, Jester PM, Sanchez PJ. et al Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015; 372: 933-943
- 16 Kimberlin DW, Lin C-Y, Sanchez PJ. et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003; 143: 16-25
- 17 Longo S, Borghesi A, Tzialla C. et al. IUGR and infections. Early Hum Dev 2014; 90 (Suppl. 01) S42-S44
- 18 Luck SE, Wieringa JW, Blázquez-Gamero D. et al. Congenital Cytomegalovirus: A European Expert Consensus Statement on Diagnosis and Management. Pediatr Infect Dis J 2017; 36: 1205-1213
- 19 Martins-Celini FP, Yamamoto AY, Passos DM. et al. Incidence, Risk Factors, and Morbidity of Acquired Postnatal Cytomegalovirus Infection Among Preterm Infants Fed Maternal Milk in a Highly Seropositive Population. Clin Infect Dis 2016; 63: 929-936
- 20 Mukhopadhyay S, Meyer S, Permar S. et al. Symptomatic Postnatal Cytomegalovirus Testing among Very Low-Birth-Weight Infants: Indications and Outcomes. Am J Perinatol 2016; 33: 894-902
- 21 Murray JC, Bernini JC, Bijou HL. et al. Infantile cytomegalovirus-associated autoimmune hemolytic anemia. J Pediatr Hematol Oncol 23: 318-320
- 22 Ogawa H, Baba Y, Suzutani T. et al. Congenital cytomegalovirus infection diagnosed by polymerase chain reaction with the use of preserved umbilical cord in sensorineural hearing loss children. Laryngoscope 2006; 116: 1991-1994
- 23 Papile LA, Burstein J, Burstein R. et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92: 529-534
- 24 Picone O, Vauloup-Fellous C, Cordier AG. et al. A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome. Prenat Diagn 2013; 33: 751-758
- 25 Rawlinson WD, Boppana SB, Fowler KB. et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis 2017; 17: e177-e188
- 26 Rawlinson WD, Hamilton ST, van Zuylen WJ. Update on treatment of cytomegalovirus infection in pregnancy and of the newborn with congenital cytomegalovirus. Curr Opin Infect Dis 2016; 29: 615-624
- 27 Rütten H, Rissmann A, Brett B. et al. Congenital cytomegalovirus infection in Central Germany: an underestimated risk. Arch Gynecol Obstet 2017; 296: 231-240
- 28 Turner KM, Lee HC, Boppana SB. et al. Incidence and Impact of CMV Infection in Very Low Birth Weight Infants. Pediatrics 2014; 133: e609-e615
- 29 Voigt M, Rochow N, Schneider K. et al. New percentile values for the anthropometric dimensions of twin neonates: analysis of perinatal survey data of 2007–2011 from all 16 states of Germany. Z Geburtshilfe Neonatol 2014; 218: 210-217
- 30 Yenicesu İ, Yetgin S, Özyürek E. et al. Virus-associated immune thrombocytopenic purpura in childhood. Pediatr Hematol Oncol 2002; 19: 433-437
- 31 Ziemann M, Krueger S, Maier AB. et al. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007; 47: 1972-1983